Digital Biotechnologies Inc., a new Seattle-based subsidiary of publicly traded immune medicine company Adaptive Biotechnologies, has raised fresh cash as part of an initial closing of a Series A investment round. Read More
With revenues declining and net losses increasing, Seattle-based Adaptive Biotechnologies on Thursday said it hired Goldman Sachs to help conduct… Read More
Adaptive Biotechnologies, which develops technology to assess the immune response, posted $154.3 million in revenue last year, a 57% year-over-year… Read More
— Seattle-based Adaptive Biotechnologies announced Nitin Sood as its first-ever chief commercial officer. Sood will report to Adaptive Biotech CEO… Read More
Seattle-based Adaptive Biotechnologies, which develops technology to sequence the human immune system to diagnose and treat disease, posted revenue of… Read More
Adaptive Biotechnologies beat expectations for its fiscal third quarter as the Seattle company continues to use its immune medicine platform… Read More
https://www.youtube.com/watch?v=gro9DtSKqos Seattle-based Adaptive Biotechnologies and Microsoft have launched an open-access database called ImmuneCODE to catalog the many ways in which… Read More
